Reclast
OVERDOSE
Clinical experience with acute overdosage of zoledronic acid (Reclast) solution for intravenous infusion is limited. Patients who have received doses higher than those recommended should be carefully monitored. Overdosage may cause clinically significant renal impairment, hypocalcemia, hypophosphatemia, and hypomagnesemia. Clinically relevant reductions in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate, respectively.
Single doses of Reclast should not exceed 5 mg and the duration of the intravenous infusion should be no less than 15 minutes [see DOSAGE AND ADMINISTRATION].
CONTRAINDICATIONS
Hypocalcemia
[see WARNINGS and PRECAUTIONS]
Hypersensitivity to zoledronic acid or any components of Reclast
Hypersensitivity reactions including rare cases of urticaria, angioedema, and anaphylactic reaction/shock have been reported [see Post-Marketing Experience].
Generic Name: Zoledronic Acid Injection
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Healthy Bones
Get tips and advances in treatment.
Calcium 101
An estimated 18 million Americans are at risk for osteoporosis. Taking the right calcium supplements now can help fight bone loss later. See more WebMD Videos »
Reclast
Health Resources
2008 Election & Health Care on WebMD. Get Informed.
Updated & New
RxList does not provide medical advice, diagnosis or treatment.